Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
| Autor: | Zhu, Andrew X, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frederic, Chung, Hyun Cheol, Baron, Ari D, Pfiffer, Tulio Eduardo Flesch, Okusaka, Takuji, Kubackova, Katerina, Trojan, Jorg, Sastre, Javier, Chau, Ian, Chang, Shao-Chun, Abada, Paolo B, Yang, Ling, Schwartz, Jonathan D, Kudo, Masatoshi |
|---|---|
| Zdroj: | In The Lancet Oncology July 2015 16(7):859-870 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|